25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ARQT (Arcutis) Stock Analysis
Buy, Hold or Sell?

Let's analyze Arcutis together

I guess you are interested in Arcutis Biotherapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Arcutis’s Financial Insights
  • 📈 Technical Analysis (TA) – Arcutis’s Price Targets

I'm going to help you getting a better view of Arcutis Biotherapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Arcutis Biotherapeutics Inc

I send you an email if I find something interesting about Arcutis Biotherapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Arcutis (30 sec.)










1.2. What can you expect buying and holding a share of Arcutis? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$1.19
Expected worth in 1 year
$1.12
How sure are you?
32.1%

+ What do you gain per year?

Total Gains per Share
$-0.07
Return On Investment
-0.3%

For what price can you sell your share?

Current Price per Share
$24.23
Expected price per share
$18.15 - $27.08
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Arcutis (5 min.)




Live pricePrice per Share (EOD)
$24.23
Intrinsic Value Per Share
$24.30 - $29.83
Total Value Per Share
$25.49 - $31.02

2.2. Growth of Arcutis (5 min.)




Is Arcutis growing?

Current yearPrevious yearGrowGrow %
How rich?$158m$164.1m-$14.8m-10.0%

How much money is Arcutis making?

Current yearPrevious yearGrowGrow %
Making money-$11m-$48.8m$37.8m341.1%
Net Profit Margin-16.3%-206.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Arcutis (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#267 / 843

Most Revenue
#108 / 843

Most Profit
#543 / 843

Most Efficient
#345 / 843
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Arcutis?

Welcome investor! Arcutis's management wants to use your money to grow the business. In return you get a share of Arcutis.

First you should know what it really means to hold a share of Arcutis. And how you can make/lose money.

Speculation

The Price per Share of Arcutis is $24.23. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Arcutis.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Arcutis, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.19. Based on the TTM, the Book Value Change Per Share is $-0.02 per quarter. Based on the YOY, the Book Value Change Per Share is $0.22 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Arcutis.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.060.2%-0.09-0.4%-0.40-1.6%-0.34-1.4%-0.40-1.7%-0.33-1.4%
Usd Book Value Change Per Share0.100.4%-0.02-0.1%0.220.9%-0.09-0.4%-0.010.0%0.040.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.100.4%-0.02-0.1%0.220.9%-0.09-0.4%-0.010.0%0.040.2%
Usd Price Per Share18.85-15.61-7.94-11.24-16.17-14.74-
Price to Earnings Ratio84.51--0.68--5.63--3.62--7.96--8.62-
Price-to-Total Gains Ratio197.93-64.94--11.85-10.38--3.76--11.99-
Price to Book Ratio15.85-13.33-5.85-10.29-10.00-9.05-
Price-to-Total Gains Ratio197.93-64.94--11.85-10.38--3.76--11.99-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share24.23
Number of shares41
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.02-0.01
Usd Total Gains Per Share-0.02-0.01
Gains per Quarter (41 shares)-0.72-0.46
Gains per Year (41 shares)-2.90-1.83
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-3-130-2-12
20-6-160-4-14
30-9-190-5-16
40-12-220-7-18
50-14-250-9-20
60-17-280-11-22
70-20-310-13-24
80-23-340-15-26
90-26-370-16-28
100-29-400-18-30

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%1.019.00.05.0%1.027.00.03.6%1.027.00.03.6%
Book Value Change Per Share2.02.00.050.0%4.08.00.033.3%7.013.00.035.0%9.018.01.032.1%9.018.01.032.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.028.00.0%0.00.028.00.0%
Total Gains per Share2.02.00.050.0%4.08.00.033.3%7.013.00.035.0%9.018.01.032.1%9.018.01.032.1%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Arcutis Biotherapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.095-0.018+119%0.220-57%-0.085+189%-0.011+112%0.042+124%
Book Value Per Share--1.1901.175+1%1.333-11%1.160+3%1.723-31%1.391-14%
Current Ratio--3.5003.600-3%6.974-50%6.578-47%11.075-68%11.685-70%
Debt To Asset Ratio--0.5740.578-1%0.623-8%0.630-9%0.460+25%0.559+3%
Debt To Equity Ratio--1.3471.377-2%1.789-25%1.982-32%1.313+3%0.957+41%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--2483046250.0001987999776.140+25%1059867825.720+134%1453457424.193+71%2144606951.652+16%2366873846.362+5%
Eps--0.056-0.089+260%-0.397+812%-0.344+717%-0.402+822%-0.333+697%
Ev To Ebitda Ratio--55.809-26.277+147%-7.594+114%-13.124+124%-14.311+126%-16.179+129%
Ev To Sales Ratio--6.2566.307-1%7.864-20%34.608-82%100.371-94%100.371-94%
Free Cash Flow Per Share---0.013-0.076+476%-0.341+2481%-0.317+2305%-0.361+2636%-0.296+2141%
Free Cash Flow To Equity Per Share---0.002-0.269+12737%0.196-101%-0.201+9495%0.000-80%0.056-104%
Gross Profit Margin--1.0001.0000%1.332-25%1.163-14%1.098-9%1.070-7%
Intrinsic Value_10Y_max--29.835----------
Intrinsic Value_10Y_min--24.297----------
Intrinsic Value_1Y_max---0.654----------
Intrinsic Value_1Y_min---0.645----------
Intrinsic Value_3Y_max--0.812----------
Intrinsic Value_3Y_min--0.719----------
Intrinsic Value_5Y_max--5.625----------
Intrinsic Value_5Y_min--4.982----------
Market Cap2967985812.160+16%2504882250.0001990728776.140+26%978482325.720+156%1404577257.527+78%1998215201.652+25%1818134159.511+38%
Net Profit Margin--0.075-0.163+318%-2.060+2858%-6.496+8798%-11.326+15265%-8.090+10932%
Operating Margin--0.106-0.112+205%-1.778+1771%-5.752+5504%-10.541+10004%-7.530+7174%
Operating Ratio--0.9141.143-20%2.910-69%7.048-87%11.503-92%8.216-89%
Pb Ratio20.369+22%15.84613.327+19%5.850+171%10.285+54%9.999+58%9.055+75%
Pe Ratio108.630+22%84.510-0.679+101%-5.628+107%-3.623+104%-7.964+109%-8.624+110%
Price Per Share24.230+22%18.85015.610+21%7.935+138%11.235+68%16.174+17%14.744+28%
Price To Free Cash Flow Ratio-458.923-29%-357.024340.577-205%-6.505-98%109.806-425%59.587-699%38.783-1021%
Price To Total Gains Ratio254.415+22%197.92564.945+205%-11.849+106%10.376+1808%-3.760+102%-11.992+106%
Quick Ratio--4.5124.716-4%10.229-56%9.780-54%17.523-74%18.202-75%
Return On Assets--0.020-0.032+261%-0.120+702%-0.114+668%-0.130+749%-0.149+847%
Return On Equity--0.047-0.078+266%-0.363+874%-0.378+906%-0.312+766%-0.255+644%
Total Gains Per Share--0.095-0.018+119%0.220-57%-0.085+189%-0.011+112%0.042+124%
Usd Book Value--158073000.000149311500.000+6%164169250.000-4%144205083.333+10%212358200.000-26%171295071.429-8%
Usd Book Value Change Per Share--0.095-0.018+119%0.220-57%-0.085+189%-0.011+112%0.042+124%
Usd Book Value Per Share--1.1901.175+1%1.333-11%1.160+3%1.723-31%1.391-14%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--2483046250.0001987999776.140+25%1059867825.720+134%1453457424.193+71%2144606951.652+16%2366873846.362+5%
Usd Eps--0.056-0.089+260%-0.397+812%-0.344+717%-0.402+822%-0.333+697%
Usd Free Cash Flow---1754000.000-9561000.000+445%-41950750.000+2292%-39039166.667+2126%-44331300.000+2427%-36293750.000+1969%
Usd Free Cash Flow Per Share---0.013-0.076+476%-0.341+2481%-0.317+2305%-0.361+2636%-0.296+2141%
Usd Free Cash Flow To Equity Per Share---0.002-0.269+12737%0.196-101%-0.201+9495%0.000-80%0.056-104%
Usd Market Cap2967985812.160+16%2504882250.0001990728776.140+26%978482325.720+156%1404577257.527+78%1998215201.652+25%1818134159.511+38%
Usd Price Per Share24.230+22%18.85015.610+21%7.935+138%11.235+68%16.174+17%14.744+28%
Usd Profit--7410000.000-11081000.000+250%-48883750.000+760%-42580500.000+675%-49704250.000+771%-40832535.714+651%
Usd Revenue--99219000.00079482250.000+25%34677000.000+186%42139833.333+135%25320150.000+292%18085821.429+449%
Usd Total Gains Per Share--0.095-0.018+119%0.220-57%-0.085+189%-0.011+112%0.042+124%
 EOD+5 -3MRQTTM+31 -6YOY+22 -163Y+31 -75Y+24 -1410Y+24 -14

3.3 Fundamental Score

Let's check the fundamental score of Arcutis Biotherapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15108.630
Price to Book Ratio (EOD)Between0-120.369
Net Profit Margin (MRQ)Greater than00.075
Operating Margin (MRQ)Greater than00.106
Quick Ratio (MRQ)Greater than14.512
Current Ratio (MRQ)Greater than13.500
Debt to Asset Ratio (MRQ)Less than10.574
Debt to Equity Ratio (MRQ)Less than11.347
Return on Equity (MRQ)Greater than0.150.047
Return on Assets (MRQ)Greater than0.050.020
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Arcutis Biotherapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5061.565
Ma 20Greater thanMa 5022.434
Ma 50Greater thanMa 10019.801
Ma 100Greater thanMa 20017.341
OpenGreater thanClose25.105
Total5/5 (100.0%)

4. In-depth Analysis

4.1 About Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand eczema and vitiligo; and ARQ-234, a CD200R fusion protein for the treatment of atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Fundamental data was last updated by Penke on 2025-11-07 09:11:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Arcutis earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Arcutis to the Biotechnology industry mean.
  • A Net Profit Margin of 7.5% means that $0.07 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Arcutis Biotherapeutics Inc:

  • The MRQ is 7.5%. The company is making a profit. +1
  • The TTM is -16.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ7.5%TTM-16.3%+23.8%
TTM-16.3%YOY-206.0%+189.7%
TTM-16.3%5Y-1,132.6%+1,116.3%
5Y-1,132.6%10Y-809.0%-323.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.5%-78.6%+86.1%
TTM-16.3%-163.3%+147.0%
YOY-206.0%-187.9%-18.1%
3Y-649.6%-262.6%-387.0%
5Y-1,132.6%-338.6%-794.0%
10Y-809.0%-470.4%-338.6%
4.3.1.2. Return on Assets

Shows how efficient Arcutis is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Arcutis to the Biotechnology industry mean.
  • 2.0% Return on Assets means that Arcutis generated $0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Arcutis Biotherapeutics Inc:

  • The MRQ is 2.0%. Using its assets, the company is less efficient in making profit.
  • The TTM is -3.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ2.0%TTM-3.2%+5.2%
TTM-3.2%YOY-12.0%+8.8%
TTM-3.2%5Y-13.0%+9.8%
5Y-13.0%10Y-14.9%+2.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.0%-11.8%+13.8%
TTM-3.2%-11.5%+8.3%
YOY-12.0%-11.2%-0.8%
3Y-11.4%-12.0%+0.6%
5Y-13.0%-11.6%-1.4%
10Y-14.9%-13.7%-1.2%
4.3.1.3. Return on Equity

Shows how efficient Arcutis is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Arcutis to the Biotechnology industry mean.
  • 4.7% Return on Equity means Arcutis generated $0.05 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Arcutis Biotherapeutics Inc:

  • The MRQ is 4.7%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is -7.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ4.7%TTM-7.8%+12.5%
TTM-7.8%YOY-36.3%+28.5%
TTM-7.8%5Y-31.2%+23.5%
5Y-31.2%10Y-25.5%-5.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.7%-13.8%+18.5%
TTM-7.8%-14.7%+6.9%
YOY-36.3%-15.1%-21.2%
3Y-37.8%-16.7%-21.1%
5Y-31.2%-16.9%-14.3%
10Y-25.5%-19.5%-6.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Arcutis Biotherapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Arcutis is operating .

  • Measures how much profit Arcutis makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Arcutis to the Biotechnology industry mean.
  • An Operating Margin of 10.6% means the company generated $0.11  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Arcutis Biotherapeutics Inc:

  • The MRQ is 10.6%. The company is operating less efficient.
  • The TTM is -11.2%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ10.6%TTM-11.2%+21.8%
TTM-11.2%YOY-177.8%+166.7%
TTM-11.2%5Y-1,054.1%+1,043.0%
5Y-1,054.1%10Y-753.0%-301.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.6%-164.5%+175.1%
TTM-11.2%-266.6%+255.4%
YOY-177.8%-248.7%+70.9%
3Y-575.2%-248.8%-326.4%
5Y-1,054.1%-331.9%-722.2%
10Y-753.0%-501.5%-251.5%
4.3.2.2. Operating Ratio

Measures how efficient Arcutis is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.91 means that the operating costs are $0.91 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Arcutis Biotherapeutics Inc:

  • The MRQ is 0.914. The company is less efficient in keeping operating costs low.
  • The TTM is 1.143. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ0.914TTM1.143-0.229
TTM1.143YOY2.910-1.767
TTM1.1435Y11.503-10.360
5Y11.50310Y8.216+3.287
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9141.898-0.984
TTM1.1432.722-1.579
YOY2.9102.848+0.062
3Y7.0483.562+3.486
5Y11.5034.571+6.932
10Y8.2166.306+1.910
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Arcutis Biotherapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Arcutis is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.50 means the company has $3.50 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Arcutis Biotherapeutics Inc:

  • The MRQ is 3.500. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.600. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.500TTM3.600-0.099
TTM3.600YOY6.974-3.374
TTM3.6005Y11.075-7.475
5Y11.07510Y11.685-0.610
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.5003.272+0.228
TTM3.6003.570+0.030
YOY6.9744.010+2.964
3Y6.5784.376+2.202
5Y11.0755.701+5.374
10Y11.6856.070+5.615
4.4.3.2. Quick Ratio

Measures if Arcutis is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Arcutis to the Biotechnology industry mean.
  • A Quick Ratio of 4.51 means the company can pay off $4.51 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Arcutis Biotherapeutics Inc:

  • The MRQ is 4.512. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.716. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.512TTM4.716-0.204
TTM4.716YOY10.229-5.513
TTM4.7165Y17.523-12.807
5Y17.52310Y18.202-0.679
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.5122.909+1.603
TTM4.7163.149+1.567
YOY10.2293.831+6.398
3Y9.7804.393+5.387
5Y17.5235.686+11.837
10Y18.2026.469+11.733
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Arcutis Biotherapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Arcutis assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Arcutis to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.57 means that Arcutis assets are financed with 57.4% credit (debt) and the remaining percentage (100% - 57.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Arcutis Biotherapeutics Inc:

  • The MRQ is 0.574. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.578. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.574TTM0.578-0.004
TTM0.578YOY0.623-0.045
TTM0.5785Y0.460+0.119
5Y0.46010Y0.559-0.099
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5740.349+0.225
TTM0.5780.364+0.214
YOY0.6230.335+0.288
3Y0.6300.353+0.277
5Y0.4600.348+0.112
10Y0.5590.379+0.180
4.5.4.2. Debt to Equity Ratio

Measures if Arcutis is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Arcutis to the Biotechnology industry mean.
  • A Debt to Equity ratio of 134.7% means that company has $1.35 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Arcutis Biotherapeutics Inc:

  • The MRQ is 1.347. The company is able to pay all its debts with equity. +1
  • The TTM is 1.377. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.347TTM1.377-0.031
TTM1.377YOY1.789-0.411
TTM1.3775Y1.313+0.064
5Y1.31310Y0.957+0.356
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3470.410+0.937
TTM1.3770.448+0.929
YOY1.7890.431+1.358
3Y1.9820.473+1.509
5Y1.3130.474+0.839
10Y0.9570.523+0.434
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Arcutis generates.

  • Above 15 is considered overpriced but always compare Arcutis to the Biotechnology industry mean.
  • A PE ratio of 84.51 means the investor is paying $84.51 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Arcutis Biotherapeutics Inc:

  • The EOD is 108.630. Based on the earnings, the company is expensive. -2
  • The MRQ is 84.510. Based on the earnings, the company is expensive. -2
  • The TTM is -0.679. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD108.630MRQ84.510+24.120
MRQ84.510TTM-0.679+85.189
TTM-0.679YOY-5.628+4.949
TTM-0.6795Y-7.964+7.284
5Y-7.96410Y-8.624+0.661
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD108.630-2.703+111.333
MRQ84.510-2.294+86.804
TTM-0.679-2.664+1.985
YOY-5.628-3.568-2.060
3Y-3.623-3.737+0.114
5Y-7.964-5.932-2.032
10Y-8.624-6.842-1.782
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Arcutis Biotherapeutics Inc:

  • The EOD is -458.923. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -357.024. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 340.577. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-458.923MRQ-357.024-101.899
MRQ-357.024TTM340.577-697.601
TTM340.577YOY-6.505+347.082
TTM340.5775Y59.587+280.990
5Y59.58710Y38.783+20.804
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-458.923-3.420-455.503
MRQ-357.024-2.907-354.117
TTM340.577-3.843+344.420
YOY-6.505-4.299-2.206
3Y109.806-5.307+115.113
5Y59.587-8.253+67.840
10Y38.783-9.824+48.607
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Arcutis is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 15.85 means the investor is paying $15.85 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Arcutis Biotherapeutics Inc:

  • The EOD is 20.369. Based on the equity, the company is expensive. -2
  • The MRQ is 15.846. Based on the equity, the company is expensive. -2
  • The TTM is 13.327. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD20.369MRQ15.846+4.523
MRQ15.846TTM13.327+2.520
TTM13.327YOY5.850+7.477
TTM13.3275Y9.999+3.328
5Y9.99910Y9.055+0.944
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD20.3692.316+18.053
MRQ15.8462.061+13.785
TTM13.3272.230+11.097
YOY5.8502.489+3.361
3Y10.2852.654+7.631
5Y9.9993.761+6.238
10Y9.0554.406+4.649
4.6.2. Total Gains per Share

2.4. Latest News of Arcutis Biotherapeutics Inc

Does Arcutis Biotherapeutics Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Arcutis Biotherapeutics Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-11-07
22:00
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Read
2025-10-31
19:22
Why Arcutis Biotherapeutics (ARQT) Is Up 23.9% After Expanding ZORYVE to Pediatric Atopic DermatitisRead
2025-10-31
14:15
Arcutis Biotherapeutics, Inc. (ARQT) Hits Fresh High: Is There Still Room to Run?Read
2025-10-24
14:00
Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE® (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology ConferenceRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Arcutis Biotherapeutics Inc.

4.8.1. Institutions holding Arcutis Biotherapeutics Inc

Institutions are holding 110.119% of the shares of Arcutis Biotherapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-06-30Suvretta Capital Management, LLC9.62064.8754115355821126040.9858
2025-06-30Jennison Associates LLC9.26520.092411109405-251470-2.2135
2025-06-30Rubric Capital Management LP8.9652.276610749457-217215-1.9807
2025-06-30BlackRock Inc7.11630.00238532761-359576-4.0437
2025-06-30Vanguard Group Inc5.87890.001670490992310213.3884
2025-06-30Polar Capital Holdings PLC4.17540.36745006475-1700000-25.3486
2025-06-30State Street Corp3.77540.00244526937527341.1786
2025-06-30Morgan Stanley - Brokerage Accounts3.59830.0039431453047598912.4003
2025-06-30Gilder Gagnon Howe & CO LLC3.46590.61854155763597121.4578
2025-06-30UBS Group AG2.45020.00712937939179310.6141
2025-06-30Franklin Resources Inc2.27910.01022732777-28990-1.0497
2025-06-30Geode Capital Management, LLC2.15380.00252582567356201.3985
2025-06-30HHG PLC1.88810.0156226396022113604204.1065
2025-06-30D. E. Shaw & Co LP1.80390.021521630011734938.7204
2025-06-30Pivotal bioVenture Partners Investment Advisor LLC1.768518.4263212050800
2025-06-30Ensign Peak Advisors Inc1.66920.0482001439130500.6563
2025-06-30Goldman Sachs Group Inc1.57650.0036189024678683371.309
2025-06-30American Century Companies Inc1.43810.01311724307718154.3459
2025-06-30Point72 Asset Management, L.P.1.23880.0409148542565494778.8639
2025-06-30GW&K Investment Management, LLC1.14960.1731378432-133779-8.8466
Total 75.276827.002390260610+2206079+2.4%

4.9.2. Funds holding Arcutis Biotherapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-07-31Polar Capital Biotech S Inc4.173.8436500000000
2025-07-31Vanguard Total Stock Mkt Idx Inv2.82750.00263390371-71750-2.0724
2025-06-30Jennison SMid Cap Core Equity2.64231.41613168209830112.6906
2025-07-31PGIM Jennison Small Company A2.64231.4902316820990660.287
2025-08-31iShares Russell 2000 ETF2.15090.0603257899900
2025-07-31PGIM Jennison Health Sciences Z1.89282.5368226951400
2025-06-30Jennison Health Sciences Equity1.89282.3369226951400
2025-08-31SPDR® S&P Biotech ETF1.57190.58188480942000.2233
2025-08-31Franklin Biotechnology Discv A(acc)USD1.34111.7481608019-77764-4.6129
2025-06-30MEDICAL BioHealth EUR Acc1.16742.9206139971900
2025-06-30American Century Small Cap Growth Inv1.11260.40471334049504283.9286
2025-06-30American Century U.S. Small Cap Growth1.11260.40591334049504283.9286
2025-07-31APO Medical Opportunities R0.98052.4999117564622058723.0967
2025-07-31Vanguard Institutional Extnd Mkt Idx Tr0.96180.02091153304-506096-30.4987
2025-06-30Fidelity Small Cap Index0.89660.05891075012-15427-1.4148
2025-08-31iShares Russell 2000 Growth ETF0.78460.117994075200
2025-07-31Franklin Biotechnology Discovery A0.75471.813904886-60659-6.2824
2025-06-30JENNISON SMALL/MID CAP EQUITY 30.67461.4477808852-114710-12.4204
2025-07-31Candriam Eqs L Biotech C USD Cap0.65920.967579043500
2025-08-31iShares Biotechnology ETF0.52330.177362751600
Total 30.759524.848836881864-428686-1.2%

5.3. Insider Transactions

Insiders are holding 1.784% of the shares of Arcutis Biotherapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-10-02Larry Todd EdwardsSELL450420.04
2025-10-02Todd WatanabeSELL2073920.04
2025-10-01Howard G WelgusSELL1000018.92
2025-10-01Todd WatanabeSELL2426119.33
2025-09-09Todd WatanabeSELL50417.52
2025-09-08Todd WatanabeSELL962517.54
2025-09-04Masaru MatsudaSELL3613016.16
2025-09-02Howard G WelgusSELL1000015.64
2025-08-21Patrick BurnettSELL243815.57
2025-08-19Patrick BurnettSELL175016.16
2025-08-08Patrick BurnettSELL384714.03
2025-08-04Todd WatanabeSELL1154714.33
2025-08-04Masaru MatsudaSELL633014.33
2025-08-04Latha VairavanSELL8914.33
2025-08-04Patrick BurnettSELL262214.33
2025-08-01Howard G WelgusSELL1000014.3
2025-07-14Patrick BurnettSELL575015.07
2025-07-10Patrick BurnettSELL2300015.05
2025-06-18Howard G WelgusSELL1013913.37
2025-06-13Patrick J HeronBUY264613.08
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-09-302024-12-312025-03-312025-06-302025-09-30
Net Debt  73,327-34,07739,25018,44657,696-20,58137,115-77,959-40,844
Income before Tax  -41,53731,072-10,465-14,316-24,7819,237-15,54423,0347,490
Net Income  -41,53730,749-10,788-14,272-25,0609,174-15,88623,2967,410
EBIT  -34,88429,970-4,914-16,885-21,7999,284-12,51523,07610,561
EBITDA  -33,45228,996-4,456-14,211-18,6676,715-11,95223,07511,123
Operating Income  -39,06631,434-7,632-16,897-24,5299,918-14,61123,1378,526



5.2. Latest Balance Sheet

Balance Sheet of 2025-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets370,977
Total Liabilities212,904
Total Stockholder Equity158,073
 As reported
Total Liabilities 212,904
Total Stockholder Equity+ 158,073
Total Assets = 370,977

Assets

Total Assets370,977
Total Current Assets349,224
Long-term Assets21,753
Total Current Assets
Cash And Cash Equivalents 47,120
Short-term Investments 143,948
Net Receivables 115,116
Inventory 22,419
Other Current Assets 20,621
Total Current Assets  (as reported)349,224
Total Current Assets  (calculated)349,224
+/-0
Long-term Assets
Property Plant Equipment 5,782
Intangible Assets 15,375
Long-term Assets Other 596
Long-term Assets  (as reported)21,753
Long-term Assets  (calculated)21,753
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities99,770
Long-term Liabilities113,134
Total Stockholder Equity158,073
Total Current Liabilities
Short-term Debt 1,000
Accounts payable 5,795
Other Current Liabilities 92,975
Total Current Liabilities  (as reported)99,770
Total Current Liabilities  (calculated)99,770
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)113,134
Long-term Liabilities  (calculated)0
+/- 113,134
Total Stockholder Equity
Common Stock12
Retained Earnings -1,155,479
Accumulated Other Comprehensive Income -62
Other Stockholders Equity 1,313,602
Total Stockholder Equity (as reported)158,073
Total Stockholder Equity (calculated)158,073
+/-0
Other
Cash and Short Term Investments 191,068
Common Stock Shares Outstanding 132,885
Liabilities and Stockholders Equity 370,977
Net Debt -40,844
Net Working Capital 249,454
Short Long Term Debt Total 6,276



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
> Total Assets 
0
0
0
51,098
38,179
38,179
28,303
107,012
254,392
231,970
198,013
298,269
471,416
432,892
387,008
408,152
364,109
300,464
508,914
449,274
379,458
320,689
292,959
341,365
478,541
444,759
437,354
348,889
344,105
352,433
370,977
370,977352,433344,105348,889437,354444,759478,541341,365292,959320,689379,458449,274508,914300,464364,109408,152387,008432,892471,416298,269198,013231,970254,392107,01228,30338,17938,17951,098000
   > Total Current Assets 
3,418
0
0
51,098
50,940
37,596
27,771
106,474
253,878
228,035
194,121
292,826
465,975
427,554
381,770
402,773
358,918
295,426
496,719
437,406
367,676
308,868
281,548
330,431
468,062
434,591
423,720
335,820
323,671
332,778
349,224
349,224332,778323,671335,820423,720434,591468,062330,431281,548308,868367,676437,406496,719295,426358,918402,773381,770427,554465,975292,826194,121228,035253,878106,47427,77137,59650,94051,098003,418
       Cash And Cash Equivalents 
-3,418
0
0
39,394
-50,940
12,823
23,177
63,336
190,893
171,546
45,707
65,082
288,690
89,128
51,778
96,449
69,795
61,512
81,543
53,641
81,405
105,114
107,471
89,323
190,714
84,887
134,851
71,335
53,104
73,048
47,120
47,12073,04853,10471,335134,85184,887190,71489,323107,471105,11481,40553,64181,54361,51269,79596,44951,77889,128288,69065,08245,707171,546190,89363,33623,17712,823-50,94039,39400-3,418
       Short-term Investments 
6,836
0
0
11,546
101,880
23,039
2,000
37,929
58,426
52,429
144,005
219,359
156,237
320,236
315,492
290,610
273,806
220,657
395,420
355,948
251,000
163,557
119,642
183,463
213,769
278,167
195,710
156,620
144,984
118,083
143,948
143,948118,083144,984156,620195,710278,167213,769183,463119,642163,557251,000355,948395,420220,657273,806290,610315,492320,236156,237219,359144,00552,42958,42637,9292,00023,039101,88011,546006,836
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
472
510
577
399
362
362
362
0
2,431
8,458
12,769
17,207
19,417
25,807
37,154
43,411
60,119
73,066
85,415
106,688
115,116
115,116106,68885,41573,06660,11943,41137,15425,80719,41717,20712,7698,4582,43103623623623995775104720000000000
       Other Current Assets 
0
0
0
40
0
1,521
2,594
5,209
4,559
3,265
4,409
7,875
21,048
17,791
14,138
15,714
14,955
13,257
13,018
11,845
13,951
12,516
21,105
19,629
13,178
14,863
19,025
20,273
23,554
18,635
20,621
20,62118,63523,55420,27319,02514,86313,17819,62921,10512,51613,95111,84513,01813,25714,95515,71414,13817,79121,0487,8754,4093,2654,5595,2092,5941,521040000
   > Long-term Assets 
-3,418
0
0
0
-50,940
583
532
538
514
3,935
3,892
5,443
5,441
5,338
5,238
5,379
5,191
5,038
12,195
11,868
11,782
11,821
11,411
10,934
10,479
10,168
13,634
13,069
20,434
19,655
21,753
21,75319,65520,43413,06913,63410,16810,47910,93411,41111,82111,78211,86812,1955,0385,1915,3795,2385,3385,4415,4433,8923,935514538532583-50,940000-3,418
       Property Plant Equipment 
0
0
0
0
536
536
485
491
467
3,857
3,814
5,365
5,363
5,260
5,160
5,301
5,113
4,960
4,742
4,602
4,704
4,413
4,190
3,900
3,633
3,510
3,246
2,994
3,338
3,122
5,782
5,7823,1223,3382,9943,2463,5103,6333,9004,1904,4134,7044,6024,7424,9605,1135,3015,1605,2605,3635,3653,8143,8574674914855365360000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,375
7,188
7,000
6,812
6,625
6,438
6,250
6,063
9,792
9,479
16,500
15,937
15,375
15,37515,93716,5009,4799,7926,0636,2506,4386,6256,8127,0007,1887,375000000000000000000
       Long-term Assets Other 
-3,418
0
0
0
-50,940
47
47
47
47
78
78
78
78
78
78
78
78
78
78
78
78
596
596
596
596
595
596
596
596
596
596
59659659659659659559659659659678787878787878787878787847474747-50,940000-3,418
> Total Liabilities 
0
0
0
75,085
4,585
4,585
81,253
172,041
12,510
23,047
24,942
27,648
20,422
18,404
24,013
110,475
110,337
105,082
238,140
239,693
239,726
240,181
246,242
252,698
253,599
258,332
280,713
191,348
201,447
213,459
212,904
212,904213,459201,447191,348280,713258,332253,599252,698246,242240,181239,726239,693238,140105,082110,337110,47524,01318,40420,42227,64824,94223,04712,510172,04181,2534,5854,58575,085000
   > Total Current Liabilities 
0
0
0
2,673
4,170
4,170
8,599
5,237
12,222
19,281
21,154
22,602
15,314
13,347
19,058
33,326
32,963
27,482
37,102
37,807
37,025
36,659
41,889
46,668
47,309
51,352
172,426
81,013
91,129
103,936
99,770
99,770103,93691,12981,013172,42651,35247,30946,66841,88936,65937,02537,80737,10227,48232,96333,32619,05813,34715,31422,60221,15419,28112,2225,2378,5994,1704,1702,673000
       Short-term Debt 
0
0
0
0
0
169
173
356
364
160
64
0
0
212
612
866
1,014
1,164
1,278
1,314
1,352
1,390
1,430
1,470
756
1,554
100,311
820
1,684
1,000
1,000
1,0001,0001,684820100,3111,5547561,4701,4301,3901,3521,3141,2781,1641,014866612212006416036435617316900000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
99,513
0
0
1,000
0
01,0000099,51300000000000000000000000000
       Accounts payable 
0
0
0
1,801
2,025
2,025
3,159
1,405
4,759
8,253
5,039
7,140
3,146
2,676
4,871
7,353
12,466
8,437
8,666
8,827
12,485
17,156
13,179
11,992
12,969
7,943
19,325
14,220
24,529
15,082
5,795
5,79515,08224,52914,22019,3257,94312,96911,99213,17917,15612,4858,8278,6668,43712,4667,3534,8712,6763,1467,1405,0398,2534,7591,4053,1592,0252,0251,801000
       Other Current Liabilities 
0
0
0
872
191
1,976
5,267
3,476
7,099
10,868
16,051
15,462
12,168
10,459
13,575
25,107
19,483
17,881
27,158
27,666
23,188
18,113
27,280
33,206
33,584
41,855
52,790
65,973
65,758
87,854
92,975
92,97587,85465,75865,97352,79041,85533,58433,20627,28018,11323,18827,66627,15817,88119,48325,10713,57510,45912,16815,46216,05110,8687,0993,4765,2671,976191872000
   > Long-term Liabilities 
0
0
0
72,412
0
415
72,654
166,804
288
3,766
3,788
5,046
5,108
5,057
4,955
77,149
77,374
77,600
201,038
201,886
202,701
203,522
204,353
206,030
206,290
206,980
108,287
110,335
110,318
109,523
113,134
113,134109,523110,318110,335108,287206,980206,290206,030204,353203,522202,701201,886201,03877,60077,37477,1494,9555,0575,1085,0463,7883,766288166,80472,654415072,412000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
72,350
72,742
73,138
196,753
0
198,763
199,767
0
0
0
0
0
0
0
0
0
000000000199,767198,7630196,75373,13872,74272,350000000000000000
       Other Liabilities 
0
0
0
0
195
195
227
184
206
156
113
82
58
25
31
25
19
12
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000121925312558821131562061842271951950000
> Total Stockholder Equity
2,161
0
0
-23,987
48,265
33,594
-52,950
-65,029
241,882
208,923
173,071
270,621
450,994
414,488
362,995
297,677
253,772
195,382
270,774
209,581
139,732
80,508
46,717
88,667
224,942
186,427
156,641
157,541
142,658
138,974
158,073
158,073138,974142,658157,541156,641186,427224,94288,66746,71780,508139,732209,581270,774195,382253,772297,677362,995414,488450,994270,621173,071208,923241,882-65,029-52,95033,59448,265-23,987002,161
   Common Stock
0
0
0
0
1
1
0
0
3
3
4
4
5
5
5
5
5
5
6
6
6
6
6
9
12
12
12
12
12
12
12
12121212121212966666555555443300110000
   Retained Earnings -1,155,479-1,162,889-1,147,003-1,121,943-1,111,155-1,069,618-1,017,286-981,904-915,620-870,855-799,864-719,764-647,745-540,036-472,630-408,306-336,980-280,000-237,992-201,950-167,901-129,697-94,285-66,272-53,704-39,223-39,223-24,276000
   Capital Surplus 
0
0
0
289
0
561
754
1,244
336,145
0
0
472,569
688,939
694,519
699,988
706,233
727,417
736,665
920,109
0
940,004
951,649
0
0
0
0
0
0
0
0
0
000000000951,649940,0040920,109736,665727,417706,233699,988694,519688,939472,56900336,1451,2447545610289000
   Treasury Stock0000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
-71,963
3
561
-71,498
1,244
336,145
338,617
340,964
472,569
688,939
694,519
699,988
706,233
727,417
736,665
920,109
930,425
940,004
951,649
962,515
1,070,558
1,242,349
1,256,327
1,267,251
1,279,479
1,289,789
1,301,886
1,313,602
1,313,6021,301,8861,289,7891,279,4791,267,2511,256,3271,242,3491,070,558962,515951,649940,004930,425920,109736,665727,417706,233699,988694,519688,939472,569340,964338,617336,1451,244-71,4985613-71,963000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue196,542
Cost of Revenue-19,128
Gross Profit177,414177,414
 
Operating Income (+$)
Gross Profit177,414
Operating Expense-305,811
Operating Income-128,397-128,397
 
Operating Expense (+$)
Research Development76,420
Selling General Administrative222,491
Selling And Marketing Expenses6,900
Operating Expense305,811305,811
 
Net Interest Income (+$)
Interest Income0
Interest Expense-27,168
Other Finance Cost-0
Net Interest Income-27,168
 
Pretax Income (+$)
Operating Income-128,397
Net Interest Income-27,168
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-139,392-117,402
EBIT - interestExpense = -139,392
-139,392
-112,871
Interest Expense27,168
Earnings Before Interest and Taxes (EBIT)-112,224-112,224
Earnings Before Interest and Taxes (EBITDA)-109,625
 
After tax Income (+$)
Income Before Tax-139,392
Tax Provision-647
Net Income From Continuing Ops-140,039-140,039
Net Income-140,039
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses324,939
Total Other Income/Expenses Net-10,99527,168
 

Technical Analysis of Arcutis
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Arcutis. The general trend of Arcutis is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Arcutis's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Arcutis Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Arcutis Biotherapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 27.08.

The bearish price targets are: 21.84 > 19.60 > 18.15.

Know someone who trades $ARQT? Share this with them.👇

Arcutis Biotherapeutics Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Arcutis Biotherapeutics Inc. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Arcutis Biotherapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Arcutis Biotherapeutics Inc. The current macd is 1.49395733.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Arcutis price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Arcutis. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Arcutis price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Arcutis Biotherapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartArcutis Biotherapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Arcutis Biotherapeutics Inc. The current adx is 45.94.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Arcutis shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Arcutis Biotherapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Arcutis Biotherapeutics Inc. The current sar is 22.10.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Arcutis Biotherapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Arcutis Biotherapeutics Inc. The current rsi is 61.56. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
Arcutis Biotherapeutics Inc Daily Relative Strength Index (RSI) ChartArcutis Biotherapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Arcutis Biotherapeutics Inc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Arcutis price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Arcutis Biotherapeutics Inc Daily Stochastic Oscillator ChartArcutis Biotherapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Arcutis Biotherapeutics Inc. The current cci is 59.73.

Arcutis Biotherapeutics Inc Daily Commodity Channel Index (CCI) ChartArcutis Biotherapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Arcutis Biotherapeutics Inc. The current cmo is 19.06.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Arcutis Biotherapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartArcutis Biotherapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Arcutis Biotherapeutics Inc. The current willr is -38.09581111.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Arcutis is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Arcutis Biotherapeutics Inc Daily Williams %R ChartArcutis Biotherapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Arcutis Biotherapeutics Inc. The current atr is 1.37198091.

Arcutis Biotherapeutics Inc Daily Average True Range (ATR) ChartArcutis Biotherapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Arcutis Biotherapeutics Inc. The current obv is 214,123,658.

Arcutis Biotherapeutics Inc Daily On-Balance Volume (OBV) ChartArcutis Biotherapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Arcutis Biotherapeutics Inc. The current mfi is 58.27.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Arcutis Biotherapeutics Inc Daily Money Flow Index (MFI) ChartArcutis Biotherapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Arcutis Biotherapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-06-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-06-23CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-25WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-30STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-07-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-10SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-14BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-15STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-18STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-07-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-07-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-01WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-08-04STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-08-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-08-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-08-15ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-19ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-08-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-09-03STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-09-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-09BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-09-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-18WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-09-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-09-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-09-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-30WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-10-01ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-10-02ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-10-03RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-10-07STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-10-09RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-10-13STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-10-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-10-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-10-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-10-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-10-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-10-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-10-27STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-10-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-10-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-11-03RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-11-06STOCH SHORT EXITThe %K line crosses above the %D line.
2025-11-07STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Arcutis Biotherapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Arcutis Biotherapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5061.565
Ma 20Greater thanMa 5022.434
Ma 50Greater thanMa 10019.801
Ma 100Greater thanMa 20017.341
OpenGreater thanClose25.105
Total5/5 (100.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Arcutis with someone you think should read this too:
  • Are you bullish or bearish on Arcutis? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Arcutis? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Arcutis Biotherapeutics Inc

I send you an email if I find something interesting about Arcutis Biotherapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Arcutis Biotherapeutics Inc.

Receive notifications about Arcutis Biotherapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.